Serum Squamous Cell Carcinoma Antigen in Psoriasis: A Potential Quantitative Biomarker for Disease Severity.

Dermatology (Basel, Switzerland) Pub Date : 2018-01-01 Epub Date: 2018-06-05 DOI:10.1159/000488672

Ziwen Sun, Xiaomin Shi, Yun Wang, Yi Zhao

{"title":"Serum Squamous Cell Carcinoma Antigen in Psoriasis: A Potential Quantitative Biomarker for Disease Severity.","authors":"Ziwen Sun, Xiaomin Shi, Yun Wang, Yi Zhao","doi":"10.1159/000488672","DOIUrl":null,"url":null,"abstract":"Background: An objective and quantitative method to evaluate psoriasis severity is important for practice and research in the precision care of psoriasis.Objectives: We aimed to explore serum biomarkers quantitatively in association with disease severity and treatment response in psoriasis patients, with serum squamous cell carcinoma antigen (SCCA) evaluated in this pilot study.Methods: 15 psoriasis patients were treated with adalimumab. At different visits before and after treatment, quantitative body surface area (qBSA) was obtained from standardized digital body images of the patients, and the psoriasis area severity index (PASI) was also monitored. SCCA were detected by using microparticle enzyme immunoassay. The serum biomarkers were also tested in healthy volunteers as normal controls. Receiver-operating characteristic (ROC) curve analysis was used to explore the optimal cutoff point of SCCA to differentiate mild and moderate-to-severe psoriasis.Results: The serum SCCA level in the psoriasis group was significantly higher (p < 0.05) than in the normal control group. After treatment, the serum SCCA levels were significantly decreased (p < 0.05). The SCCA level was well correlated with PASI and qBSA. In ROC analysis, when taking PASI = 10 or qBSA = 10% as the threshold, an optimal cutoff point of SCCA was found at 2.0 ng/mL with the highest Youden index.Conclusion: Serum SCCA might be a useful quantitative biomarker for psoriasis disease severity.","PeriodicalId":144585,"journal":{"name":"Dermatology (Basel, Switzerland)","volume":" ","pages":"120-126"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000488672","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology (Basel, Switzerland)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000488672","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/6/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 8

Abstract

Background: An objective and quantitative method to evaluate psoriasis severity is important for practice and research in the precision care of psoriasis.

Objectives: We aimed to explore serum biomarkers quantitatively in association with disease severity and treatment response in psoriasis patients, with serum squamous cell carcinoma antigen (SCCA) evaluated in this pilot study.

Methods: 15 psoriasis patients were treated with adalimumab. At different visits before and after treatment, quantitative body surface area (qBSA) was obtained from standardized digital body images of the patients, and the psoriasis area severity index (PASI) was also monitored. SCCA were detected by using microparticle enzyme immunoassay. The serum biomarkers were also tested in healthy volunteers as normal controls. Receiver-operating characteristic (ROC) curve analysis was used to explore the optimal cutoff point of SCCA to differentiate mild and moderate-to-severe psoriasis.

Results: The serum SCCA level in the psoriasis group was significantly higher (p < 0.05) than in the normal control group. After treatment, the serum SCCA levels were significantly decreased (p < 0.05). The SCCA level was well correlated with PASI and qBSA. In ROC analysis, when taking PASI = 10 or qBSA = 10% as the threshold, an optimal cutoff point of SCCA was found at 2.0 ng/mL with the highest Youden index.

Conclusion: Serum SCCA might be a useful quantitative biomarker for psoriasis disease severity.

查看原文本刊更多论文

银屑病血清鳞状细胞癌抗原:疾病严重程度的潜在定量生物标志物。

背景:建立客观、定量的银屑病严重程度评价方法，对银屑病精准护理的实践和研究具有重要意义。目的:我们旨在定量探索银屑病患者血清生物标志物与疾病严重程度和治疗反应的相关性，并在本初步研究中评估血清鳞状细胞癌抗原(SCCA)。方法:对15例银屑病患者进行阿达木单抗治疗。在治疗前后的不同就诊时间，对患者的标准化数字身体图像获取定量体表面积(qBSA)，并监测银屑病区域严重程度指数(PASI)。采用微颗粒酶免疫法检测SCCA。血清生物标志物也在健康志愿者中作为正常对照进行了测试。采用受试者工作特征(Receiver-operating characteristic, ROC)曲线分析，探讨SCCA鉴别轻度和中重度牛皮癣的最佳截断点。结果:银屑病组血清SCCA水平显著高于正常对照组(p < 0.05)。治疗后血清SCCA水平显著降低(p < 0.05)。SCCA水平与PASI和qBSA呈正相关。在ROC分析中，以PASI = 10或qBSA = 10%为阈值时，发现SCCA的最佳临界值为2.0 ng/mL，约登指数最高。结论:血清SCCA可作为银屑病严重程度的定量生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology (Basel, Switzerland)

自引率

0.00%

发文量